A phase 2 trial of IMC-001 in advanced solid tumours, run by ImmuneOncia Therapeutics Inc., now recruiting.
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor is a phase 2 interventional study registered as NCT06365840 by ImmuneOncia Therapeutics Inc., with 30 participants planned, started 2025-01-13 and due to reach its primary completion in 2027-06-30. Interventions recorded: IMC-001.
Shares ImmuneOncia Therapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.